Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Adaptive Biotechnologies
company
About
Adaptive Biotechnologies translates scale and precision of the adaptive immune system into products to diagnose and treat disease.
- Seattle,Washington,United States
- 251 - 500
- http://adaptivebiotech.com
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $125M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2009
- Number Of Employee
- 251 - 500
- Operating Status
- Active
- Stock Symbol
- nasdaq:ADPT
- Legal Name
- Adaptive Biotechnologies Corporation
- Also Known As
- Adaptive TCR
Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.It was founded in 2009 and headquartered in Seattle, Washington.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
12
$831.85M
Adaptive Biotechnologies has raised a total of
$831.85M
in funding over 2 rounds. Their latest funding was raised on
Sep 12, 2022 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 12, 2022 | Post-IPO Debt | $125M | 1 |
OrbiMed
|
— | Detail |
| Mar 24, 2022 | Post-IPO Equity | — | 1 |
ARK Investment Management
|
— | Detail |
| Jul 14, 2020 | Post-IPO Equity | — | — | — | — | Detail |
| Jun 26, 2019 | IPO | $300M | — | — | — | Detail |
| Mar 5, 2018 | Secondary Market | — | 1 | — | — | Detail |
Investments
Number of Investments
Number of Lead Investments
2
0
Adaptive Biotechnologies has made 2 investments. Their most recent investment was on
Dec 28, 2021, when Entropy raised $1.95M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 28, 2021
Entropy
|
Pre-seed | $1.95M | Blockchain | — |
|
Oct 19, 2021
Element Finance
|
Series A | $32M | Blockchain | — |
Investors
Number of Lead Investors
Number of Investors
5
8
Adaptive Biotechnologies is funded by 8 investors.
OrbiMed
and ARK Investment Management
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
OrbiMed
|
Yes | Post-IPO Debt |
|
ARK Investment Management
|
Yes | Post-IPO Equity |
Matrix Capital Management
|
Yes | Series F |
Viking Global Investors
|
Yes | Series D |
EquityZen
|
— | Secondary Market |
|
|
— | Series F |
Senator Investment Group
|
— | Series F |
Tiger Management Corporation
|
— | Series F |
Employee Profiles
Number of Employee Profiles
36
Adaptive Biotechnologies has 36 current employee profiles, including
Employee William Atienza
Employee
Executive
Executive
Executive
Board member
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
